|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9107
|
|
pubmed:dateCreated |
1998-9-23
|
|
pubmed:abstractText |
Despite the availability of potent antibiotics and intensive care, mortality rates from septic shock are 40-70%. We assessed the safety and efficacy of murine monoclonal antibody to human tumour necrosis factor alpha (TNF alpha MAb) in the treatment of septic shock.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
pubmed-author:AbrahamEE,
pubmed-author:AllredRR,
pubmed-author:AnzuetoAA,
pubmed-author:BaughmanRR,
pubmed-author:BermanSS,
pubmed-author:ConstantJJ,
pubmed-author:CooneyRR,
pubmed-author:Dal NogareAA,
pubmed-author:GutierrezGG,
pubmed-author:LevyHH,
pubmed-author:LightR BRB,
pubmed-author:NasrawaySS,
pubmed-author:PenningtonJJ,
pubmed-author:PooleLL,
pubmed-author:PorterSS,
pubmed-author:RumbakMM,
pubmed-author:San PedroGG,
pubmed-author:TesslerSS,
pubmed-author:WunderinkRR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
28
|
|
pubmed:volume |
351
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
929-33
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9734938-Adult,
pubmed-meshheading:9734938-Aged,
pubmed-meshheading:9734938-Antibodies, Monoclonal,
pubmed-meshheading:9734938-Double-Blind Method,
pubmed-meshheading:9734938-Female,
pubmed-meshheading:9734938-Humans,
pubmed-meshheading:9734938-Infusions, Intravenous,
pubmed-meshheading:9734938-Male,
pubmed-meshheading:9734938-Middle Aged,
pubmed-meshheading:9734938-Multiple Organ Failure,
pubmed-meshheading:9734938-Prospective Studies,
pubmed-meshheading:9734938-Shock, Septic,
pubmed-meshheading:9734938-Survival Analysis,
pubmed-meshheading:9734938-Treatment Outcome,
pubmed-meshheading:9734938-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
|
|
pubmed:affiliation |
University of Colorado Health Sciences Center, Denver 80262, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
